InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction
Little Rock, AR – InterveXion Therapeutics, a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IXT-m200, also known as ch-mAb7F9, an investigational drug candidate for the...read more
InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users
LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break...read more
The company is pleased to report publication of the results of the first human study of ch-mAb7F9. The paper was published in the journal Mabs in early November. Abstract – This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an...read more
InterveXion Therapeutics (Little Rock, AR) is a pharmaceutical company whose mission is to discover and advance innovative medications that reduce the impact of human suffering on individuals and communities. Our vision is to be a leader in the development of antagonist therapies that neutralize toxins in the body and thereby improve patient health. InterveXion’s first medications are a monoclonal antibody (mAb) and an active vaccine for treating methamphetamine (METH) abuse.